Skip to main content
Top
Published in: Globalization and Health 1/2019

Open Access 01-12-2019 | Research

Importance of the intellectual property system in attempting compulsory licensing of pharmaceuticals: a cross-sectional analysis

Author: Kyung-Bok Son

Published in: Globalization and Health | Issue 1/2019

Login to get access

Abstract

Background

Recently, interest in compulsory licensing of pharmaceuticals has been growing regardless of a country’s income- level. We aim to investigate the use of compulsory licensing as a legitimate part of the patent system and tool for the government to utilize by demonstrating that countries with a mature patent system were more likely to utilize compulsory licensing of pharmaceuticals.

Methods

We used a multivariate logistic model to regress attempts to issue compulsory licensing on the characteristics of the intellectual property system, controlling for macro context variables and other explanatory variables at a country level.

Results

A total 139 countries, selected from members of the World Trade Organization, were divided into a CL-attempted group (N = 24) and a non-CL-attempted group (N = 115). An attempt to issue compulsory licensing was associated with population (+) and a dummy variable for other regions, including Europe and North America (−). After controlling for macro context variables, mature intellectual property system was positively associated with attempting compulsory licensing.

Conclusions

Our study provided evidence of an association between attempting compulsory licensing and matured patent systems. This finding contradicts our current understanding of compulsory licensing, such as compulsory licensing as a measure to usurp traditional patent systems and sometimes diametrically opposed to the patent system. The findings also suggest a new role of compulsory licensing in current patent systems: compulsory licensing could be a potential alternative or complement to achieve access to medicines in health systems through manufacturing and exporting patented pharmaceuticals.
Literature
1.
go back to reference Son K-B, Lee T-J. Compulsory licensing of pharmaceuticals reconsidered: current situation and implications for access to medicines. Global Public Health. 2017:1–11. Son K-B, Lee T-J. Compulsory licensing of pharmaceuticals reconsidered: current situation and implications for access to medicines. Global Public Health. 2017:1–11.
2.
3.
go back to reference FM’t Hoen E, Veraldi J, Toebes B, Hogerzeil HV. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016. Bulletin of the World Health Organization. 2018;96(3):185.PubMedCrossRef FM’t Hoen E, Veraldi J, Toebes B, Hogerzeil HV. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016. Bulletin of the World Health Organization. 2018;96(3):185.PubMedCrossRef
4.
go back to reference Son K-B, Lee T-J. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: implications for domestic legislations in low-and middle-income countries. Global Public Health. 2018;13(9):1169–78.PubMedCrossRef Son K-B, Lee T-J. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: implications for domestic legislations in low-and middle-income countries. Global Public Health. 2018;13(9):1169–78.PubMedCrossRef
5.
go back to reference Kuek V, Phillips K, Kohler JC. Access to medicines and domestic compulsory licensing: learning from Canada and Thailand. Global public health. 2011;6(2):111–24.PubMedCrossRef Kuek V, Phillips K, Kohler JC. Access to medicines and domestic compulsory licensing: learning from Canada and Thailand. Global public health. 2011;6(2):111–24.PubMedCrossRef
6.
go back to reference United Nations. Report of the United Nations secretary General’s high-level panel on access to medicines. 2016. United Nations. Report of the United Nations secretary General’s high-level panel on access to medicines. 2016.
7.
go back to reference Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, De Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet. 2017;389(10067):403–76.PubMedCrossRef Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, De Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet. 2017;389(10067):403–76.PubMedCrossRef
8.
go back to reference Parliament E. EU options for improving access to medicines; 2017. Parliament E. EU options for improving access to medicines; 2017.
9.
go back to reference Feldman J. Compulsory licenses: the dangers behind the current practice. J Int'l Bus & L. 2009;8:137. Feldman J. Compulsory licenses: the dangers behind the current practice. J Int'l Bus & L. 2009;8:137.
10.
go back to reference Taylor J. Compulsory licensing: a misused and abused international trade law; 2017. Taylor J. Compulsory licensing: a misused and abused international trade law; 2017.
11.
go back to reference Monte WN. Compulsory licensing of patents. Inf Commun Technol Law. 2016;25(3):247–71.CrossRef Monte WN. Compulsory licensing of patents. Inf Commun Technol Law. 2016;25(3):247–71.CrossRef
12.
go back to reference Maybarduk P, Rimmington S. Compulsory licenses: a tool to improve global access to the HPV vaccine? American J Law Med. 2009;35(2–3):323–50.CrossRef Maybarduk P, Rimmington S. Compulsory licenses: a tool to improve global access to the HPV vaccine? American J Law Med. 2009;35(2–3):323–50.CrossRef
13.
go back to reference Heller MA, Eisenberg RS. Can patents deter innovation? The anticommons in biomedical research. Science. 1998;280(5364):698–701.PubMedCrossRef Heller MA, Eisenberg RS. Can patents deter innovation? The anticommons in biomedical research. Science. 1998;280(5364):698–701.PubMedCrossRef
14.
go back to reference Saroha S, Kaushik D, Nanda A. Compulsory licensing of drug products in developing countries. J Generic Med. 2015;12(3–4):89–94.CrossRef Saroha S, Kaushik D, Nanda A. Compulsory licensing of drug products in developing countries. J Generic Med. 2015;12(3–4):89–94.CrossRef
15.
go back to reference Ramani SV, Urias E. Access to critical medicines: when are compulsory licenses effective in price negotiations? Soc Sci Med. 2015;135:75–83.PubMedCrossRef Ramani SV, Urias E. Access to critical medicines: when are compulsory licenses effective in price negotiations? Soc Sci Med. 2015;135:75–83.PubMedCrossRef
16.
go back to reference Ford N, Wilson D, Chaves GC, Lotrowska M, Kijtiwatchakul K. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. Aids. 2007;21:S21–S9.PubMedCrossRef Ford N, Wilson D, Chaves GC, Lotrowska M, Kijtiwatchakul K. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. Aids. 2007;21:S21–S9.PubMedCrossRef
17.
go back to reference Brand O. The dawn of compulsory patent licensing. Intellect Prop Q. 2007;2:216. Brand O. The dawn of compulsory patent licensing. Intellect Prop Q. 2007;2:216.
18.
go back to reference Penrose ET. The economics of the international patent system: Baltimore. Md: Johns Hopkins Press. 1951. Penrose ET. The economics of the international patent system: Baltimore. Md: Johns Hopkins Press. 1951.
19.
go back to reference Medicines law & Policy. The TRIPS flexibilities database. 2019. Medicines law & Policy. The TRIPS flexibilities database. 2019.
20.
go back to reference Abbott FM, Reichman JH. The Doha Round's public health legacy: strategies for the production and diffusion of patented medicines under the amended TRIPS provisions. J Int Econ Law. 2007;10(4):921–87.CrossRef Abbott FM, Reichman JH. The Doha Round's public health legacy: strategies for the production and diffusion of patented medicines under the amended TRIPS provisions. J Int Econ Law. 2007;10(4):921–87.CrossRef
21.
go back to reference Bird RC. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects. J Law, Med Ethics. 2009;37(2):209–21.CrossRef Bird RC. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects. J Law, Med Ethics. 2009;37(2):209–21.CrossRef
22.
go back to reference Cohen-Kohler JC, Forman L, Lipkus N. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the agreement on trade-related aspects of intellectual property rights (TRIPS) and the imposition of TRIPS-plus standards. Health Econ, Policy Law. 2008;3(3):229–56.CrossRef Cohen-Kohler JC, Forman L, Lipkus N. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the agreement on trade-related aspects of intellectual property rights (TRIPS) and the imposition of TRIPS-plus standards. Health Econ, Policy Law. 2008;3(3):229–56.CrossRef
23.
go back to reference Ravvin M. Incentivizing access and innovation for essential medicines: a survey of the problem and proposed solutions. Public Health Ethics. 2008;1(2):110–23.CrossRef Ravvin M. Incentivizing access and innovation for essential medicines: a survey of the problem and proposed solutions. Public Health Ethics. 2008;1(2):110–23.CrossRef
24.
go back to reference Flynn M. Origins and limitations of state-based advocacy: Brazil’s AIDS treatment program and global power dynamics. Polit Soc. 2013;41(1):3–28.CrossRef Flynn M. Origins and limitations of state-based advocacy: Brazil’s AIDS treatment program and global power dynamics. Polit Soc. 2013;41(1):3–28.CrossRef
25.
go back to reference Son K-B, Kim C-Y, Lee T-J. Understanding of for whom, under what conditions and how the compulsory licensing of pharmaceuticals works in Brazil and Thailand: a realist synthesis. Global public health. 2018. Son K-B, Kim C-Y, Lee T-J. Understanding of for whom, under what conditions and how the compulsory licensing of pharmaceuticals works in Brazil and Thailand: a realist synthesis. Global public health. 2018.
26.
go back to reference Persson T, Tabellini G. Political economics and macroeconomic policy. Handb Macroecon. 1999;1:1397–482.CrossRef Persson T, Tabellini G. Political economics and macroeconomic policy. Handb Macroecon. 1999;1:1397–482.CrossRef
27.
go back to reference Marshall MG, Jaggers K. Dataset users’ manual: political regime characteristics and transitions, 1800–2006. POLITY IV PROJECT. Marshall MG, Jaggers K. Dataset users’ manual: political regime characteristics and transitions, 1800–2006. POLITY IV PROJECT.
28.
go back to reference Liu M, La Croix S. A cross-country index of intellectual property rights in pharmaceutical inventions. Res Policy. 2015;44(1):206–16.CrossRef Liu M, La Croix S. A cross-country index of intellectual property rights in pharmaceutical inventions. Res Policy. 2015;44(1):206–16.CrossRef
29.
go back to reference La Croix S, Liu M. The effect of GDP growth on pharmaceutical patent protection, 1945-2005. Brussels Econ Rev 2009;52(3/4):355–375. La Croix S, Liu M. The effect of GDP growth on pharmaceutical patent protection, 1945-2005. Brussels Econ Rev 2009;52(3/4):355–375.
30.
go back to reference Liu M, La Croix S. The impact of stronger property rights in pharmaceuticals on innovation in developed and developing countries. Honolulu: University of Hawaii at Mānoa; 2014. Liu M, La Croix S. The impact of stronger property rights in pharmaceuticals on innovation in developed and developing countries. Honolulu: University of Hawaii at Mānoa; 2014.
31.
go back to reference Luo J, Oliveira MA, Ramos MB, Maia A, Osorio-de-Castro CG. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004–2011. BMC Public Health. 2014;14(1):367.PubMedPubMedCentralCrossRef Luo J, Oliveira MA, Ramos MB, Maia A, Osorio-de-Castro CG. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004–2011. BMC Public Health. 2014;14(1):367.PubMedPubMedCentralCrossRef
32.
go back to reference Bracha O. The adventures of the statute of Anne in the land of unlimited possibilities: the life of a legal transplant. Berkeley Technol Law J. 2010;25(3):1427–73. Bracha O. The adventures of the statute of Anne in the land of unlimited possibilities: the life of a legal transplant. Berkeley Technol Law J. 2010;25(3):1427–73.
33.
go back to reference FM't Hoen E. Private patents and public health: changing intellectual property rules for access to medicines: health action international; 2016. FM't Hoen E. Private patents and public health: changing intellectual property rules for access to medicines: health action international; 2016.
34.
go back to reference Lybecker KM, Fowler E. Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules. J Law, Med Ethics. 2009;37(2):222–39.CrossRef Lybecker KM, Fowler E. Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules. J Law, Med Ethics. 2009;37(2):222–39.CrossRef
35.
go back to reference Gorecki PK, Henderson I. Compulsory patent licensing of drugs in Canada: a comment on the debate. Canadian Public Policy/Analyse de Politiques. 1981:559–68.CrossRef Gorecki PK, Henderson I. Compulsory patent licensing of drugs in Canada: a comment on the debate. Canadian Public Policy/Analyse de Politiques. 1981:559–68.CrossRef
36.
go back to reference Ford S. Compulsory licensing provisions under the TRIPS agreement: balancing pills and patents. Am U Int'l L Rev. 1999;15:941. Ford S. Compulsory licensing provisions under the TRIPS agreement: balancing pills and patents. Am U Int'l L Rev. 1999;15:941.
37.
go back to reference McCabe KW. The January 1999 review of article 27 of the TRIPS agreement: diverging views of developed and developing countries toward the patentability of biotechnology. J Intell Prop L. 1998;6:41. McCabe KW. The January 1999 review of article 27 of the TRIPS agreement: diverging views of developed and developing countries toward the patentability of biotechnology. J Intell Prop L. 1998;6:41.
38.
go back to reference von Falck A. Compulsory licenses as a defense in pharmaceutical and biotech patent litigation. Pharmaceutical patent analyst. 2016;5(6):351–3.CrossRef von Falck A. Compulsory licenses as a defense in pharmaceutical and biotech patent litigation. Pharmaceutical patent analyst. 2016;5(6):351–3.CrossRef
39.
go back to reference t Hoen EFM, Boulet P, Baker BK. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: a proposal for greater coherence in European pharmaceutical legislation. J Pharmaceutical Policy Pract. 2017;10(1):19.CrossRef t Hoen EFM, Boulet P, Baker BK. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: a proposal for greater coherence in European pharmaceutical legislation. J Pharmaceutical Policy Pract. 2017;10(1):19.CrossRef
40.
go back to reference Francisco M. Compulsory license bandwagon gains momentum. Nat Publ Group. 2012. Francisco M. Compulsory license bandwagon gains momentum. Nat Publ Group. 2012.
41.
go back to reference Miller Canfield PLC. China allows compulsory licensing. 2012. Miller Canfield PLC. China allows compulsory licensing. 2012.
42.
go back to reference Germany CMS. German Federal Court of justice upholds provisional compulsory license for HIV drugs; 2017. Germany CMS. German Federal Court of justice upholds provisional compulsory license for HIV drugs; 2017.
Metadata
Title
Importance of the intellectual property system in attempting compulsory licensing of pharmaceuticals: a cross-sectional analysis
Author
Kyung-Bok Son
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Globalization and Health / Issue 1/2019
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/s12992-019-0485-7

Other articles of this Issue 1/2019

Globalization and Health 1/2019 Go to the issue